Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

In this communication, we report the discovery of 1S (apremilast), a novel potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-alpha inhibitor. The optimization of previously reported 3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-3-(3,4-dimethoxyphenyl)propionic acid PDE4 inhibitors led to this series of sulfone analogues. Evaluation of the structure-activity relationship of substitutions on the phthalimide group led to the discovery of an acetylamino analogue 1S, which is currently in clinical trials.

[1]  M. Pal,et al.  Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. , 2008, Journal of medicinal chemistry.

[2]  B. Strober,et al.  An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast* , 2008 .

[3]  P. Barnes,et al.  Inflammation, Oxidative Stress and Systemic Effects in Mild Chronic Obstructive Pulmonary Disease , 2007, International journal of immunopathology and pharmacology.

[4]  J. Weinberg,et al.  Biological therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab and alefacept , 2006 .

[5]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[6]  J. Odingo.  Inhibitors of PDE4: a review of recent patent literature , 2005 .

[7]  B. Lipworth.  Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease , 2005, The Lancet.

[8]  M. Trevethick,et al.  PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. , 2004, Trends in pharmacological sciences.

[9]  M. Billah,et al.  The role of neutrophils in LPS-induced changes in pulmonary function in conscious rats. , 2004, Pulmonary pharmacology & therapeutics.

[10]  J. O'Donnell,et al.  Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). , 2004, Trends in pharmacological sciences.

[11]  G. Livera,et al.  Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling* , 2003, The Journal of Biological Chemistry.

[12]  J. Barsig,et al.  In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. , 2001, The Journal of pharmacology and experimental therapeutics.

[13]  M. Minnicozzi,et al.  Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. , 2001, Pulmonary pharmacology & therapeutics.

[14]  L. Corral,et al.  Thalidomide analogs and PDE4 inhibition. , 1998, Bioorganic & medicinal chemistry letters.

[15]  G. Kaplan,et al.  Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. , 1996, Journal of medicinal chemistry.

[16]  P. Barnes.  Novel signal transduction modulators for the treatment of airway diseases. , 2006, Pharmacology & therapeutics.